Skip to main content
OPCHOption Care Health, Inc.Sell5.2·$21.11+5.13%
Open full analysis

Option Care Health, Inc. (OPCH) Stock Analysis

Recovery setup

SellModerate Confidence

Healthcare · Medical Care Facilities

Sell if holding. Multiple concerning factors at $21.11: Concentration risk — Supplier: top-4 pharmaceutical vendors (68.0%); V7 low-quality RISK_OFF penalty: -0.5 (Q=4.1).

Option Care Health is the largest independent provider of home and alternate site infusion services, operating 196 locations in 43 states with a multidisciplinary team of over 5,000 clinicians. Revenue is generated through reimbursement from managed care organizations (88% of... Read more

$21.11+20.3% A.UpsideScore 5.2/10#19 of 27 Medical Care Facilities
QualityF-score7 / 9FCF yield5.35%
Stop $19.63Target $25.39(analyst − 13%)A.R:R 2.4:1
Analyst target$29.18+38.2%11 analysts
$25.39our TP
$21.11price
$29.18mean
$39

Sell if holding. Multiple concerning factors at $21.11: Concentration risk — Supplier: top-4 pharmaceutical vendors (68.0%); V7 low-quality RISK_OFF penalty: -0.5 (Q=4.1). Chart setup: Death cross but MACD improving, RSI 52. Score 5.2/10, moderate confidence.

Passes 7/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, news events none recent, earnings proximity 50d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated 2026-06-09
TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Wed, Jul 29, 202650d to earnings· next earnings call

Thesis

Rewards
Sector modifier (Healthcare): +0.5
Attractive valuation
Analyst upside: 20%
Risks
Concentration risk — Supplier: top-4 pharmaceutical vendors (68.0%)
V7 low-quality RISK_OFF penalty: -0.5 (Q=4.1)
Earnings estimates trending DOWN

Key Metrics

P/E (TTM)15.7
P/E (Fwd)9.8
Mkt Cap$3.2B
EV/EBITDA10.6
Profit Mgn3.6%
ROE15.3%
Rev Growth1.3%
Beta0.65
DividendNone
Rating analysts18

Quality Signals

Piotroski F7/9

Options Flow

P/C0.09bullish
IV70%elevated
Max Pain$40+89.5% vs spot

Concentration Risks(10-K Item 1A)

  • HIGHSuppliertop-4 pharmaceutical vendors68%
    10-K Item 1: 'approximately 68% of the Company’s pharmaceutical and medical supply purchases were from four vendors.'
  • LOWCustomerlargest payer14%
    10-K Item 1: 'The Company’s largest payer represented approximately 14% of its revenue for the year ended December 31, 2025.'

Material Events(8-K, last 90d)

  • 2026-05-05Item 5.02LOW
    Christopher Grashoff (Chief Growth Officer) departing effective May 8, 2026. Entitled to separation benefits per Executive Severance Plan. No successor named for the role.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

3 floor-breakers

Growth below the gate floor. Component breakdown shows what dragged the score down.static

Earnings Growth
2.7
Revenue Growth
2.8

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Growth Rank
0.7
Quality Rank
4.4
Value Rank
6.9

Technicals below the gate floor. Component breakdown shows what dragged the score down.static

52w Position
1.5
Bollinger
3.5
Support Resistance
3.9
Gap
5.0
GatesDeath cross (50MA < 200MA)Executive change: officer departure/appointmentMomentum 6.6>=5.5A.R:R 2.4 ≥ 1.5Insider activity: OKNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 50d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARRecoverySuitability: Aggressive
RSI
52 · Neutral
20D MA 50D MA 200D MADEATH CROSSSupport $19.34Resistance $22.25

Price Targets

$20
$25
A.Upside+20.3%
A.R:R2.4:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeRisk-Off

Analyst Consensus

Analysts18
Consensus4.2/5
Avg Target$29

Earnings

B
B
M
M
2/4 beats
Next Earnings2026-07-29 (50d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is OPCH stock a buy right now?

Sell if holding. Multiple concerning factors at $21.11: Concentration risk — Supplier: top-4 pharmaceutical vendors (68.0%); V7 low-quality RISK_OFF penalty: -0.5 (Q=4.1). Chart setup: Death cross but MACD improving, RSI 52. Prior stop was $19.63. Score 5.2/10, moderate confidence.

What is the OPCH stock price target?

Take-profit target: $25.39 (+20.3% upside). Prior stop was $19.63. Stop-loss: $19.63.

What are the risks of investing in OPCH?

Concentration risk — Supplier: top-4 pharmaceutical vendors (68.0%); V7 low-quality RISK_OFF penalty: -0.5 (Q=4.1); Earnings estimates trending DOWN.

Is OPCH overvalued or undervalued?

Option Care Health, Inc. trades at a P/E of 15.7 (forward 9.8). TrendMatrix value score: 7.7/10. Verdict: Sell.

What do analysts say about OPCH?

18 analysts cover OPCH with a consensus score of 4.2/5. Average price target: $29.

What does Option Care Health, Inc. do?Option Care Health is the largest independent provider of home and alternate site infusion services, operating 196...

Option Care Health is the largest independent provider of home and alternate site infusion services, operating 196 locations in 43 states with a multidisciplinary team of over 5,000 clinicians. Revenue is generated through reimbursement from managed care organizations (88% of revenue) and direct government programs (12%), with the largest payer representing approximately 14% of 2025 revenue.

Related stocks: ASTH (Astrana Health Inc.) · ARDT (Ardent Health, Inc.) · AVAH (Aveanna Healthcare Holdings Inc) · MD (Pediatrix Medical Group, Inc.) · CON (Concentra Group Holdings Parent)
Home Stocks OPCH

Latest news

Latest News

GuruFocus47d ago
Yahoo Finance47d agoEarnings
TipRanks47d ago
Cổng thông tin điện tử tỉnh Tây Ninh54d ago
Yahoo Finance54d ago
Yahoo Finance55d agoEarnings
StockStory46d ago
Yahoo Finance46d agoEarnings
Finviz46d ago
GuruFocus46d ago
The Malone Telegram46d agoLegal
Quiver Quantitative46d ago
GlobeNewswire46d agoLegal
Seeking Alpha46d ago
Seeking Alpha46d ago
MarketBeat46d agoEarnings
Investing.com46d ago
GuruFocus46d agoEarnings
StockStory46d ago
Marketscreener.com46d agoEarnings
Loading more...